Palo Alto, California-based CV Therapeutics announced that its heart-imaging drug met the primary endpoint in a Phase III pivotal trial. Regadenoson is intended to increase blood flow and dilate coronary arteries so that a scan will reveal any threatening blockages and restrictions. Many patients increase their blood flow for the procedure with exercise, but a large group are physically incapable of doing it. The trial compared Regadenoson to Adenoscan from Astellas, which is partnered with CV on developing Regadenoson. A second Phase III trial is currently underway.
- read this story from the San Francisco Business Times for more